NSCLC HER3-DXd Breakthrough? Insights from Resistant Cases – HERTHENA-Lung02 Results Lung Cancer Treatment 3 Mins Read This report examines the NSCLC HER3-DXd breakthrough. It focuses on its potential impact on patients with resistant EGFR-mutated non-small cell…
Osimertinib: Game-Changing Treatment Non-Small Cell Lung Cancer Lung Cancer Treatment 5 Mins Read In ASCO 2023, the highly anticipated results of the Adora study were unveiled, providing valuable insights into the efficacy and impact…
Tagrisso the Final ADAURA OS Analysis in Stage IB to IIIA EGFR-Mutated NSCLC Non-Small Cell Lung Cancer 3 Mins Read Roy Herbst, MD, PhD, from the Yale Cancer Center and Yale School of Medicine, presented a groundbreaking abstract at the…
